Understanding why severe COVID-19 triggers devastating cytokine storms has remained one of the pandemic's most clinically consequential mysteries. A new mechanistic answer — one that bypasses the virus's canonical entry route — could reshape how researchers approach both COVID-19 treatment and the broader problem of macrophage-driven lung immunopathology.
Macrophages recruited to infected lungs carry surprisingly low levels of ACE2, the receptor SARS-CoV-2 typically exploits to enter cells. Yet these same macrophages are consistently found laden with viral particles in post-mortem tissue — a paradox that this Nature Communications study resolves through a previously underappreciated pathway. When SARS-CoV-2 infects epithelial or other permissive cells, those dying cells release apoptotic bodies (ApoBDs), large extracellular vesicles generated during programmed cell death. Critically, these ApoBDs package intact, infectious virions. Macrophages are naturally primed to engulf apoptotic debris through a process called efferocytosis — and in doing so, they inadvertently internalize viable virus. Once inside, the virus activates both inflammasome signaling and NF-κB pathways, two master regulators of the cytokine cascade. The team then screened for pharmacological disruption of this cycle and identified T-type voltage-gated calcium channel (T-channel) blockers as capable of impairing ApoBD biogenesis by limiting the extracellular calcium influx required for their formation — reducing viral cell-to-cell transmission and lung inflammation in model systems.
This finding is potentially paradigm-shifting for several reasons. First, it provides a mechanistic explanation for a long-standing clinical observation that ACE2 expression alone cannot account for macrophage infection. Second, T-channel blockers are an established drug class (including agents like mibefradil and some antihypertensives), offering a repurposing rationale worth investigating in human trials. Key caveats apply: the study's lung immunopathology data derive from model systems, not human clinical outcomes, and efferocytosis efficiency may vary considerably across disease stages and patient populations. Still, by identifying apoptotic body trafficking as a druggable node in COVID-19 pathogenesis, this work opens a genuinely novel therapeutic avenue.